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Abstract: Previous studies suggest that up to 60% of all patients with hypertension receive inappropriate
treatment. Current 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC)
guidelines recommend taking cardiovascular risk factors into account when assessing treatment for pa-
tients with hypertension. The authors hypothesize that this approach will reduce the proportion of
patients receiving inappropriate treatment. In this cross- sectional study using electronic medical records
of Swiss primary care patients, the authors estimate the proportion of patients receiving inappropriate
treatment using two approaches: (1) based on a blood pres-sure threshold of 140/90 mm Hg; and (2)
based on cardiovascular risk factors. A total of 22 434 patients with hypertension were identified. Based
on these approaches, 72.7% and 44.6% of patients, respectively, qualified for drug treatment. In addition,
23.0% and 10.8% of patients, respectively, received inappropriate treatment. Application of the 2013
ESH/ESC guidelines reduced the proportion of patients receiving inappropriate treatment by 50%. This
shows the major impact of risk adjust-ment and highlights the need for a patient- centered approach in
hypertension treatment.
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1  | INTRODUCTION
Elevated blood pressure (BP) is a leading risk factor for premature 
death, stroke, and heart disease worldwide.1–3 A broad armament 
ofevidence-basedtreatmentoptionsaswellasguidelinesproviding
thelatestevidenceonhowtousethesedifferenttreatmentoptions
exist.3–7 Nevertheless, there is suspicion that a considerable pro-
portion of patients diagnosedwith hypertensionworldwide do not
receive appropriate treatment. Different studies have found a sub-
stantialgapbetweenguidelinerecommendationsandtheactualtreat-
mentofhypertensioninpatients.8–15Thisgapisoftenreferredtoas
the evidence- performance gap (EPG).16,17 Approximately 60% or more 
patientswithhypertensionworldwide,especiallypatients treated in
primarycaresettings,mightbeaffectedbytheEPG.Theseprevious










alized risk- adjusted assessment whenever deciding on hypertension 
treatment.Apossibleexplanation for theEPG is thatprimarycare
physicians (PCPs) adapt guideline recommendations to the needs
of their real-life patients, a finding that has been shown in diabe-
tes management.22 Thus, EPGs might rather be explained by an 
individualized risk- adjusted assessment than by low adherence to 
guidelines.23
The latest guidelines of the European Society of Hypertension 
(ESH) and the European Society of Cardiology (ESC) published in 2013 
recommend a broader and more individualized approach whenever 
assessingtreatmentoptionsofpatientswithhypertension.Thisnew
risk-adjusted approach takes other CVR factors, patients’ age, and
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Previousstudiessuggestthatupto60%ofallpatientswithhypertensionreceivein-
appropriate treatment. Current 2013 European Society of Hypertension/European 
Society of Cardiology (ESH/ESC) guidelines recommend taking cardiovascular risk 
factors intoaccountwhenassessingtreatmentforpatientswithhypertension.The
authorshypothesizethatthisapproachwillreducetheproportionofpatientsreceiv-
ing inappropriate treatment. In this cross-sectional study using electronic medical
recordsofSwissprimarycarepatients,theauthorsestimatetheproportionofpatients
receiving inappropriate treatment using two approaches: (1) based on a blood pres-
sure threshold of 140/90 mm Hg; and (2) based on cardiovascular risk factors. A total 
of22434patientswithhypertensionwere identified.Basedon theseapproaches,
72.7%and44.6%ofpatients,respectively,qualifiedfordrugtreatment.Inaddition,
23.0% and 10.8% of patients, respectively, received inappropriate treatment.
Application of the 2013 ESH/ESC guidelines reduced the proportion of patients
 receiving inappropriate treatment by 50%. This shows the major impact of risk adjust-
ment and highlights the need for a patient-centered approach in hypertension
treatment.
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frailty into account. At present, the 2013 ESH/ESC guidelines are the 
clinical standard for themanagementof patientswithhypertension
in Europe.
However,theproportionofpatientswithhypertensionwhoqual-
ify for treatment according to these guidelines remains unknown, as it 
istruefortheproportionofpatientsaffectedbytheEPG.
We hypothesize that the risk- adjusted approach will result in a 




cal records of primary care patients with hypertension registered
betweenJanuary2009andAugust2015.Weestimatedthepropor-
tion of patients qualifying for treatment according to two different
approaches and assessed whether PCPs had prescribed treatment or 
not.Theprimaryoutcomeofthestudywastheproportionofpatients
who did not receive treatment although recommended by guidelines. 
Bydefinition,thesepatientswereconsideredasbeingaffectedbyan
EPG.The secondaryoutcomewas thedifferencebetween theEPG
estimationsobtainedbythetwoapproaches.
First, patients were stratified according to the BP threshold
of 140/90 mm Hg, subsequently referred to as “standardized BP 
approach.”Second,patientswerestratifiedtoCVRcategoriesaccord-
ing toBP levelsandadditionalCVRfactorsas recommended in the
2013 ESH/ESC guidelines, subsequently referred to as “risk- adjusted 
approach.”24
2.1 | Data collection
Medical record data were extracted from the database of the Family 
Medicine ICPC-Research Using ElectronicMedical Records (FIRE)
project. FIRE is an ongoing research project of the Institute of
Primary Care at the University and University Hospital of Zurich,
Switzerland, involving PCPs in the German- speaking part of 
Switzerland. PCPs voluntarily provide standardized, anonymized 
medicalrecorddataofallpatientencountersindailypractice.Data
includepatients’ demographics,vital signs, diagnostic codesusing







August 2015 were assessed for the eligibility criterion hypertension.
The definition of hypertensionwas based on the occurrence of
at least one of the following criteria (which were searched for in the 
following hierarchically order):
• morethantwoBPmeasurements≥140/90mmHgor
• at least one recorded ICPC-2 coding (K85 “elevated blood pres-
sure,” K86 “hypertension uncomplicated,” K87 “hypertension com-
plicated”) or
• at least twoprescriptions for antihypertensivedrugs according to
ATC coding as validated by Lamers and colleagues29(C02“antihyper-
tensives,”C03A“low-ceilingdiuretics,thiazides,”C03EA01“hydro-
chlorothiazide and potassium-sparing agents,” C07 “beta-blocking 
agents,” C08 “calcium channel blockers,” C09A “ACE inhibitors, plain,” 
C09B“ACEinhibitors,combinations”)andATCcodingofangiotensin









of the three inclusion criteria was used as the inclusion date. The end 
date was the date of the latest visit a BP measurement was made. 
ICPC- 2 codes were used if they occurred only once, as these codes 
werebasedonbestmedicalpracticebyparticipatingPCPswhodid
the coding by themselves. ATC codes were used if they occurred at 
leasttwicetoavoidprescriptionerrors.Weusedthelatestavailable
data for changing parameters (eg, laboratory data or demographic data 
suchasweight)goingbackwardstartingattheenddate.
2.3 | Baseline characteristics
The following baseline characteristics of included patients were
assessed based on medical record entries: “age,” “antihyperten-
sive drugs,” “concomitant nonantihypertensive drugs,” “concomitant
chronic diseases,” “BP measurements,” “risk factors,” and “asympto-
maticorgandamage.”Patients’ chroniccomorbiditieswereassessed
basedontheICPC-2classificationasrecommendedbyO’Halloranand
colleages30 and based on PCGs.29
2.4 | Stratification according to BP levels 
(standardized BP approach)
We established five hypertension grade groups: normal (systolic BP
[SBP] ≤129mmHg and diastolic BP [DBP] ≤84mmHg), high nor-
mal (SBP 130–139 mm Hg, DBP 85–89 mm Hg), grade 1 (SBP 140–
159 mm Hg, DBP 90–99 mm Hg), grade 2 (SBP 160–179 mm Hg, DBP 
100–109mmHg),andgrade3(SBP≥180mmHg,DBP≥110mmHg).24
Patientswerestratifiedtothesegroupsbasedonthemeanvalue
of all recorded BP measurements. As recommended by the 2013 ESC/
ESHguidelines,stratificationtoaspecifichypertensiongradegroup
was based on the higher level, regardless of whether it was SBP or 
DBP. If two BP measurements were available from the same visit, we 
used the mean of the two available values.
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2.5 | Stratification according to CVR categories  
(risk- adjusted approach)
As recommended by the 2013 ESH/ESC guidelines, we estab-
lished eight CVR categories: average, low, low- moderate, moderate, 
moderate- high, high, high- very high, and very high depending on 
thepatients’ hypertensiongradegroupandnumberof existing risk
factors, asymptomatic organ damage, and established diseases (see
Figure 1 for details). Therefore, we searched each patient’s latest
medicalrecordforICPC-2diagnoses,medicationlists/ATCcodes,and
laboratory results (Table 1).
2.6 | Treatment criteria
All patients stratified to hypertension grade ≥1 group qualified for
drug treatment according to the standardized BP approach.
Allpatientswithhypertensiongrade≥1groupwithaCVRcate-






mean SBP level of >140 mm Hg and a mean DBP level of <90 mm Hg 




In order to assess possible changes in clinical practice over the
observation period of 6years, we performed a sensitivity analysis
comparingpatientswithinthefirst3yearswithpatientswithinthelast





Continuous variables are presented as means and standard devia-
tions(SDs)andcategoricaldataasfrequenciesandpercentages.We
usedWalds interval to calculate theconfidence interval (CI).36 Data 
analysis was performed using R statistics software (version 3.2.0;
RFoundation,Vienna,Austria).
F IGURE  1 Stratification of patients. BP, blood pressure; DBP, diastolic blood pressure;  SBP, systolic blood pressure;  HT, hypertension; CKD, 




























No other RF • No BP interventionn=116
















1-2 RF • No BP interventionn=900
• Lifestyle changes
















≥3 RF • No BP interventionn=208
• Lifestyle changes
















OD, CKD stage 3, 
or diabetes
• No BP intervention
n=0
• Lifestyle changes

















CKD stage ≥4, or
diabetes with 
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• No BP intervention
n=0
• Lifestyle changes
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3  | RESULTS
UntilAugust2015,264641primarycarepatientswereregisteredin
theFIREdatabase.All patientswere assessed for theeligibility cri-
terion hypertension and 48602were defined as eligible.Of these,
20236 patients were excluded because they had fewer than two
BPmeasurements available, 312 patients had fewer than twoPCP
consultations,5613patientswereyoungerthan18years,andseven
patientswerepregnant.Dataontheremaining22434patientswith










Based on the BP threshold of 140/90 mm Hg, 72.7% (95% CI, 72.0–
73.4)ofallpatientsqualifiedfordrugtreatment.About49.7%(95%
CI, 48.8–50.1) received a drug as recommended, while 23.0% (95% CI, 
21.8–24.1) receivednodrugsalthough theyqualified for treatment.
The latter were therefore identified as being affected by the EPG
(Figure 3).
3.2 | Risk- adjusted approach
Based on the CVR categories, 44.6% (95% CI, 43.6–45.6) of all 
patients qualified for drug treatment. A total of 33.9% (95% CI,
32.8–34.9) received a drug as recommended, while 10.8% (95% CI, 
9.5–12.0) receivednodrugsalthoughtheyqualifiedfortreatment.
The latterwere therefore identified as being affected by the EPG
(Figure 3).
3.3 | Difference between approaches
The proportion of patients affected by the EPG differed by 12.2%




the moderate- high or to a lower CVR category. Accordingly, 46.8% 
(10 493/22 434) were assigned to higher CVR categories, but only 
TABLE  1 Definitionofriskfactors,asymptomaticorgandamage,andestablisheddisease




cholesterin >4.9 mmol/L or low- density lipoprotein >3.0 mmol/L or 
triglycerides >1.7 mmol/L, or male sex and high- density lipoprotein 
<1.0 mmol/L or female sex and high- density lipoprotein <1.2 mmol/L
Obesity ICPC-2code(obesity)orBMI≥30
Elevatedfastingglucose Fastingglucoselevelbetween5.6mmol/Land6.9mmol/L
Asymptomaticorgandamage Pulse pressure Differencebetweensystolicanddiastolicbloodpressure≥60mmHgandage
≥65y(ageassessedondateofstudyinclusion)
Chronic kidney disease Grade 3 Glomerularfiltrationratebetween30mL/min/1.73m2 and 60 mL/min/1.73 m2 
according to CKD- EPI formulaa
Established disease Chronic kidney disease Grade 4 Glomerularfiltrationrate<30mL/min/1.73m2 according to CKD- EPI 
formulaa
Diabetes Useofantidiabeticmedication(ATCA10A,A10B,A10X)orICPC-2






transient cerebral ischemia, stroke/cerebrovascular accident, cerebrovascular 
disease,arteriosclerosis/PVD,retinopathy)
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8.1% (1816/22 434) were assigned to the “very high” CVR category. 
Results of stratification of patients to differentCVR categories are
shown in Figure 1.
The age stratification of all 2416 patients affected by the risk-
adjusted EPG approach showed that 11.1% (266/2416) of these 
patientswere 60years or younger,while 88.9% (2150/2416)were
older than 60 years (Figure 4).
Amongpatientsyoungerthan60years,threepatientswereiden-
tifiedasbeingaffectedbyISH.






with hypertension treated in Swiss primary care to evaluate the pro-
portionofpatientswhoqualifyfortreatmentandareaffectedbythe
EPG. That way, we were able to demonstrate the actual impact of 
individualized risk adjustment compared with assessment based on a 
rigid BP threshold.
Using the standardizedBP approach, the proportionof patients
withhypertensionwhoqualifiedfordrugtreatmentwas72.7%com-
pared with 44.6% using the risk-adjusted approach, resulting in a
difference of 28.1%.The proportion of patients identified as being






at least one of three inclusion criteria:
Two BP measurements >140/90 mm Hg (n=22'762)
Diagnose of hypertension (ICPC2 code)  (n=8'533)











excluded due to exclusion criteria:
Only one BP measurement available (n=20'236)*
Only one consultation with primary care physician (n=312)
Age younger than 18 years (n=5'613)
Pregnancy (n=7)
n=22'434   
Standardized BP 
approach
Analysis according to 
BP threshold
of 140/90 mm Hg                
n=264'641








Our results using the standardized BP approach are comparable 
to previous studies that only used the standardized BP approach and 
neglected patients’ individual CVR factors. Some of these studies
describedadecreaseof theEPGovertimebutattributed it to rea-
sons such as a healthier lifestyle, increase of drug treatment, or higher 
awareness of hypertension.10,11,13,14,37,38





ease and had an average age of 38 years. Moreover, this approach was 
based on a number of assessment criteria that is currently considered 
outdated.12
Recently, Navar- Boggan and colleagues39 demonstrated that the 
introductionofanewguidelineforhypertensionmanagementinthe
United States significantly changed the proportion of patientswho
qualifiedfortreatment.
Applying the2013ESH/ESCguidelines,wearenowthefirst to






on the source.24,32–35,40 Therefore, we refrained from using a clear age 
threshold when assessing appropriateness of treatment. Nevertheless, 
one should keep in mind that the observed EPG might further decrease 
dependingonthedefinitionof“elderly.”
In addition to age, but partially associated with age, there are
otherfactorssuchaspatientfrailty,orthostatichypotension,vertigo,
social circumstances, individual compliance, and preferences, as well 
ascomorbiditiesandpreexistingpolypharmacy,thatmightinfluence
the decision process. One faces the challenge of balancing advantages 
and disadvantages of additional treatment based on these factors.
Obviously, additional treatment aswell as concomitant chronic dis-
ease will complicate the decision.41Inthisstudy,patientshadamean
of 4.8 concomitant chronic diseases and received 5.9 concomitant 
drugs. These circumstances emphasize that more effective studies
inprimary care areneeded inorder todefine theevidencebaseof
treatment,sincepatientswithmultimorbiddiseasewithconcomitant
polypharmacyareoftenexcludedfromguideline-influencingrandom-
ized controlled trials. For example, one of the latest studies on the 
topic of BP management excluded patients affected by dementia,
diabetes, history of stroke, and those living in a nursing home who 
arecommonlyfoundintheprimarycaresetting.42 This study among 
patientswith high CVR targeting an SBP of <120mmHg, as com-
pared with <140 mm Hg, resulted in lower rates of fatal and nonfa-
tal major cardiovascular events and death from any cause, although 
F IGURE  3 Patients with hypertension. BP, blood pressure; CI, confidence interval
Risk-adjusted approach
Included patients with hypertension
(n=22'434, 100%)






95% CI, 72.0 to 73.4)




95% CI, 9.5 to 12.0)
Evidence performance 
gap
















95% CI, 48.8 to 50.1)




95% CI, 21.8 to 24.1)
Evidence performance 
gap
 Standardized BP approach
Included patients with hypertension
(n=22'434, 100%)
→ →
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the intensive-treatmentgroupexperienced significantlyhigher rates
of some adverse events.42,43 These results, supported by data from 
a largemeta-analysis,will influence futureguidelinesandstress the
importanceofriskadjustmentandpatient-centeredness.44
4.1 | Strengths und limitations
In our dataset, the prevalence of hypertension is seemingly low com-
paredwithotherstudiesintheprimarycaresetting.9,10,14,21,45-47 This 
isexplainedbyexclusionofpatientswhohadfewerthantwoencoun-
ters with their PCP and/or fewer than two BP measurements. This 
decisionwas takenbecausewe aimed to specifically analyzePCPs’
treatmentperformance,asitisunlikelythatPCPshaveaninfluence
onpatients’hypertensiontreatmentwithoutregularcontact.Leaving
these patients within our analysis, the prevalence of patients with




ical records. Therefore, they are subject to the usual limitations of
routinedata.48,49Weassessedpatients’CVRprofileaccordingtothe
2013 ESH/ESC guidelines, but some variables (ie, smoking, abdominal 
obesity, family history for premature cardiovascular diseases, and indi-
catorsforasymptomaticorgandamage)werelimitedornotavailable
in our dataset. However, PCPs base their daily decisions on the same 
variablesaswedidwhenextractingdatafromtheirmedicalrecords.





















High normal (SBP 130–139 mm Hg or DBP 85–89 mm Hg) 4900 21.8
Grade 1 (SBP 140–159 mm Hg or DBP 90–99 mm Hg) 12 672 56.5
Grade 2 (SBP 160–179 mm Hg or DBP 100–110 mm Hg) 3118 13.9
Grade3(SBP≥180mmHgorDBP≥110mmHg) 520 2.3
Risk factors
Male sex 11 364 50.7





Pulsepressure≥60mmHg(inpatients≥65y) 12 736 56.8
Chronic kidney disease Grade 3c 2184 21.8
Established disease
Chronic kidney disease Grade 4c 238 2.4
Diabetes 918 4.1
Cardiovascular disease 1041 4.6













hypertension are treated in this setting.8,9,12,42 Most likely, our data 
cannot be generalized to other care settings, but countrieswith an
equalhealthsystemshouldtaketheseresultsasasuggestiontorevisit
previousEPGestimations.Switzerlandservesasagoodexampleofan
industrialized country with an insurance- based healthcare system with 
a fee- for- service reimbursement and mostly free choice of doctors–a 
model that can also be found in other countries, eg, Austria, France, 
Germany,andpartsoftheUnitedStates.Theestimationoftheactual
risk- adjusted EPG in Swiss primary care will thus allow an extrapola-
tionoftheEPGinthesecountries.
5  | CONCLUSIONS
Application of the risk-adjusted approach as recommended by the
2013 ESH/ESC guidelines reduced the EPG by more than 50%. 
This demonstrates the major impact of risk adjustment and high-
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